ANDA Avalanche: How Will FDA Deal With The 600 Received This Month?
Executive Summary
Experts say one idea may be to borrow some new drug staff to help relieve the pressure; FDA says it will use all available resources.
You may also be interested in...
ANDA Submissions Lagging As FY2023 Nears Its End
Generic drug sponsors are on pace to submit the second-fewest number of ANDAs in a fiscal year in the history of GDUFA.
ANDA Submissions Lagging As FY 2023 Nears Its End
Generic drug sponsors are on pace to submit the second-fewest number of ANDAs in a fiscal year in the history of GDUFA.
Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals
ANDA approval rates have remained steady, while submission rates dropped compared to prior years.